Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacnotuzumab + spartalizumab in advanced malignancies
NCT02807844Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of lacnotuzumab in triple-negative breast cancer (TNBC), pancreatic carcinoma, endometrial carcinoma, melanoma, sponsored by Novartis. Started Jun 2016; status: completed.
02
Drugs
lacnotuzumab
03
Conditions
triple-negative breast cancer (TNBC)pancreatic carcinomaendometrial carcinomamelanoma
Beyond the preview
Go deeper on NCT02807844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807844.